There are more than 1 million functional endoscopic sinus surgery (FESS) surgeries performed annually in the United States and Europe. In the past several years, the sinus market has seen a number of acquisitions and significant raises.

  • ArthroCare purchased ENTrigue for $45 million (June 2013).
  • J&J acquired Acclarent for $785 million (January 2010).
  • Intersect raised $30 million from Northwest VP (2013).
  • Entellus raised $35 million from Covidien VC (2011).

Besides chronic sinusitis, additional markets for S.T. Stent include nose job failures, chronic allergic rhinitis, and a direct stenting alternative to replace sinuplasty.